Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Non-Current Liabilities (2016 - 2024)

VYNE Therapeutics' Total Non-Current Liabilities history spans 9 years, with the latest figure at $25000.0 for Q2 2024.

  • For Q2 2024, Total Non-Current Liabilities fell 99.61% year-over-year to $25000.0; the TTM value through Jun 2024 reached $25000.0, down 99.61%, while the annual FY2023 figure was $1.4 million, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $25000.0 in Q2 2024 per VYNE's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $58.9 million in Q2 2021 to a low of $25000.0 in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $20.0 million, with a median of $8.0 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 67.85% in 2021, then plummeted 99.61% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $34.5 million in 2020, then crashed by 36.27% to $22.0 million in 2021, then tumbled by 69.83% to $6.6 million in 2022, then crashed by 78.71% to $1.4 million in 2023, then tumbled by 98.23% to $25000.0 in 2024.
  • Per Business Quant, the three most recent readings for VYNE's Total Non-Current Liabilities are $25000.0 (Q2 2024), $1.4 million (Q1 2024), and $1.4 million (Q4 2023).